A Universal Cyclodextrin‐Based Nanovaccine Platform Delivers Epitope Peptides for Enhanced Antitumor Immunity
Advanced Healthcare Materials · 2023
DOI: 10.1002/adhm.202301099 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Healthcare Materials, 2023. Verfasst von Jiarong Mao und 9 weiteren Autor:innen. Beteiligte Einrichtung: The Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing, 210000, P. R. China. Hauptthemen laut MEDLINE: Cancer Vaccines, Neoplasms, Nanoparticles. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 48 Literaturangaben. Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
Currently, there is still an intense demand for a simple and scalable delivery platform for peptide‐based cancer vaccines. Herein, a cyclodextrin‐based polymer nanovaccine platform (CDNP) is designed for the codelivery of peptides with two immune adjuvants [the Toll‐like receptor (TLR)7/8 agonist R848 and the TLR9 agonist CpG] that is broadly applicable to epitope peptides with diverse sequences. Specifically, the cyclodextrin‐based polymers are covalently linked to epitope peptides via a bioreactive bond‐containing cross‐linker (PNC‐DTDE‐PNC) and then physically load with R848 and CpG to obtain CDNP. The CDNP efficiently accumulats in the lymph nodes (LNs), greatly facilitating antigen capture and cross‐presentation by antigen‐presenting cells. The immunogenicity of the epitope peptides is significantly enhanced by the codelivery and synergy of the adjuvants, and the CDNP shows the ability to inhibit tumor progression in diverse tumor‐bearing mouse models. It is concluded that CDNP holds promise as an optimized peptide‐based cancer vaccine platform.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- The Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing, 210000, P. R. China.
- School of Pharmacy, Nanjing University of Chinese Medicine, Nanjing, 210000, P. R. China.
ORCID-Profile: Jingjing Wang
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Mao, J., Jin, Z., Rui, X., Li, L., Hou, C., Leng, X., Bi, X., Chen, Z., Chen, Y., & Wang, J. (2023). A Universal Cyclodextrin‐Based Nanovaccine Platform Delivers Epitope Peptides for Enhanced Antitumor Immunity. Advanced Healthcare Materials. https://doi.org/10.1002/adhm.202301099
Vancouver
Mao J, Jin Z, Rui X, Li L, Hou C, Leng X, et al. A Universal Cyclodextrin‐Based Nanovaccine Platform Delivers Epitope Peptides for Enhanced Antitumor Immunity. Advanced Healthcare Materials. 2023. doi:10.1002/adhm.202301099
BibTeX
@article{Mao2023,
author = {Mao, Jiarong and Jin, Zhetong and Rui, Xue and Li, Lu and Hou, Chengchen and Leng, Xuejiao and Bi, Xiaolin and Chen, Zhipeng and Chen, Yugen and Wang, Jingjing},
title = {A Universal Cyclodextrin‐Based Nanovaccine Platform Delivers Epitope Peptides for Enhanced Antitumor Immunity},
journal = {Advanced Healthcare Materials},
year = {2023},
doi = {10.1002/adhm.202301099}
}
EUVIMED